PMID- 17552048
OWN - NLM
STAT- MEDLINE
DCOM- 20070816
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 34
IP  - 7
DP  - 2007 Jul
TI  - Changes in biomarkers of inflammation and bone turnover and associations with 
      clinical efficacy following infliximab plus methotrexate therapy in patients with 
      early rheumatoid arthritis.
PG  - 1465-74
AB  - OBJECTIVE: To determine if changes in biomarkers of inflammation and bone 
      turnover in response to treatment with infliximab plus methotrexate (MTX) versus 
      MTX alone are associated with improvement in clinical measures of signs, 
      symptoms, and structural damage in early rheumatoid arthritis. METHODS: Sera were 
      collected from patients in the ASPIRE study who received 3 mg/kg (n = 48) or 6 
      mg/kg infliximab plus MTX (n = 55), or MTX alone (n = 41). Several baseline 
      biomarker levels correlated with changes in median percentage of American College 
      of Rheumatology improvement (ACR-N), 50% improvement in ACR response (ACR50), and 
      van der Heijde-modified Sharp score (vdHSS) at Week 54. RESULTS: Infliximab plus 
      MTX treatment resulted in more rapid decreases in levels of matrix 
      metalloproteinase-3 (MMP-3), intercellular cell adhesion molecule-1, interleukin 
      8 (IL-8), and tumor necrosis factor-a than treatment with MTX alone. Baseline 
      levels and decreases from baseline to Weeks 6 and 54 in MMP-3 correlated with 
      improvement in ACR-N response at Week 54. An increase in IL-8 levels from 
      baseline to Week 54 correlated with worsening in vdHSS at Week 54 in the 
      MTX-alone group. Regression analysis of markers at baseline showed that MMP-3 was 
      the only variable associated with ACR50 response and less worsening in vdHSS at 
      Week 54. CONCLUSION: Treatment with infliximab plus MTX resulted in a rapid 
      decrease in inflammation markers. MMP-3 levels at different timepoints were 
      consistently associated with clinical improvements at Week 54 in the infliximab 
      plus MTX group, while increases in IL-8 levels correlated with a worsening in 
      vdHSS at Week 54 in the MTX-alone group.
FAU - Visvanathan, Sudha
AU  - Visvanathan S
AD  - Centocor, Inc., Malvern, Pennsylvania, USA. SVisvana@CNTUS.JNJ.COM
FAU - Marini, Joseph C
AU  - Marini JC
FAU - Smolen, Josef S
AU  - Smolen JS
FAU - Clair, E William St
AU  - Clair EW
FAU - Pritchard, Charles
AU  - Pritchard C
FAU - Shergy, William
AU  - Shergy W
FAU - Pendley, Charles
AU  - Pendley C
FAU - Baker, Daniel
AU  - Baker D
FAU - Bala, Mohan
AU  - Bala M
FAU - Gathany, Timothy
AU  - Gathany T
FAU - Han, John
AU  - Han J
FAU - Wagner, Carrie
AU  - Wagner C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20070601
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - B72HH48FLU (Infliximab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy/physiopathology
MH  - Biomarkers/*blood
MH  - Bone Remodeling/*drug effects/physiology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Infliximab
MH  - Male
MH  - Methotrexate/*therapeutic use
MH  - Middle Aged
MH  - Severity of Illness Index
EDAT- 2007/06/07 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/06/07 09:00
PHST- 2007/06/07 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/06/07 09:00 [entrez]
AID - 07/13/061 [pii]
PST - ppublish
SO  - J Rheumatol. 2007 Jul;34(7):1465-74. Epub 2007 Jun 1.